Cell No. 1 Interpretation of a cancer cell, provided by Angela Canada Hopkins, daughter of a cancer patient.

Committed to advancing new medicines to benefit patients with viral-associated cancers and other serious diseases.

Cell No. 1 Interpretation of a cancer cell, provided by Angela Canada Hopkins, daughter of a cancer patient.

Who We Are

Viracta is clinical-stage drug development company focused on advancing new therapies to address a broad range of cancers and virus-associated diseases.

Who We Are

Viracta is clinical-stage drug development company focused on advancing new therapies to address a broad range of cancers and virus-associated diseases.

Recent News

June 3, 2019

Viracta Presents New Clinical Results on Lead Epigenetic Drug Candidate for EBV-Associated Lymphomas at the 2019 ASCO Annual Meeting - Viracta Therapeutics, Inc. presented updated results today at the 2019 ASCO Annual Meeting from the Ph1b portion of the ongoing Phase 1b/2 clinical trial of nanatinostat in combination with the antiviral valganciclovir for the treatment of relapsed/refractory EBV-associated lymphomas. Read More

May 15, 2019

Viracta to Present New Clinical Results on Lead Epigenetic Drug Candidate Nanatinostat at the 2019 ASCO Annual Meeting - Viracta Therapeutics, Inc. announced today that it will present new clinical data during a poster session at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting to be held May 31 to June 4, 2019 in Chicago, IL. Read More

Events

June 19-21, 2019

Viracta will be doing a poster presentation at the 2019 ICML meeting in Lugano. Read More

May 31-June 4, 2019

Some of the team will be attending the Chicago, IL ASCO Meeting. Read More

May 29, 2019

Our CEO, Dr. Ivor Royston, will be winning a lifetime achievement award at the upcoming Xconomy San Diego Awards Gala. Read More

Recent News

June 3, 2019

Viracta Presents New Clinical Results on Lead Epigenetic Drug Candidate for EBV-Associated Lymphomas at the 2019 ASCO Annual Meeting - Viracta Therapeutics, Inc. presented updated results today at the 2019 ASCO Annual Meeting from the Ph1b portion of the ongoing Phase 1b/2 clinical trial of nanatinostat in combination with the antiviral valganciclovir for the treatment of relapsed/refractory EBV-associated lymphomas. Read More

May 15, 2019

Viracta to Present New Clinical Results on Lead Epigenetic Drug Candidate Nanatinostat at the 2019 ASCO Annual Meeting - Viracta Therapeutics, Inc. announced today that it will present new clinical data during a poster session at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting to be held May 31 to June 4, 2019 in Chicago, IL. Read More

Events

June 19-21, 2019

Viracta will be doing a poster presentation at the 2019 ICML meeting in Lugano. Read More

May 31-June 4, 2019

Some of the team will be attending the Chicago, IL ASCO Meeting. Read More

May 29, 2019

Our CEO, Dr. Ivor Royston, will be winning a lifetime achievement award at the upcoming Xconomy San Diego Awards Gala. Read More